Semaglutide vs Tirzepatide Cost: Which Is More Affordable?

When you’re choosing between semaglutide and tirzepatide, the clinical question and the cost question are two different conversations. Tirzepatide produces stronger average weight loss in clinical trials. Semaglutide has a longer track record and wider insurance coverage. But for many people, neither of those factors is the deciding one. What actually determines which medication they pursue is price.

Here’s a straightforward comparison of what each medication costs across brand-name, compounded, and insurance-covered scenarios, so you can make a decision based on your actual situation rather than list prices alone.

Brand-Name List Prices

Starting with retail pricing gives you the ceiling, which is useful context even if you won’t end up paying full price.

Semaglutide brand-name medications are Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Ozempic lists at roughly $900 to $1,000 per month. Wegovy lists at approximately $1,300 to $1,400 per month. The difference between them comes down to approved indication, dosing, and market positioning, which is covered in detail if you want to understand why the Ozempic vs Wegovy price gap exists.

Tirzepatide brand-name medications are Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management). Mounjaro lists at roughly $1,000 to $1,100 per month. Zepbound lists at approximately $1,060 to $1,100 per month, making it somewhat closer in price to Mounjaro than the semaglutide equivalents are to each other.

At full retail, tirzepatide runs modestly higher than semaglutide across comparable indications, though the gap has narrowed as Zepbound’s pricing has been positioned more competitively than Wegovy’s.

Insurance Coverage Comparison

Insurance coverage is where the real cost divergence happens for most patients.

Semaglutide, specifically Ozempic, has broader insurance coverage than any other GLP-1 medication. Because it’s been approved for type 2 diabetes since 2017 and carries cardiovascular risk reduction labeling, most commercial insurers and Medicare Part D plans include it on their formularies for diabetic patients. Patients with a qualifying diagnosis often pay $25 to $100 per month depending on their plan.

Wegovy coverage for weight loss is inconsistent. Some commercial plans cover it, many don’t, and prior authorization requirements are common. Does Insurance Cover Wegovy breaks down the coverage landscape by plan type if you want to check your specific situation.

Mounjaro coverage follows a similar pattern to Ozempic: reasonably broad for type 2 diabetes patients with commercial insurance, more restricted for weight loss. Zepbound coverage for weight management is growing but still variable. Eli Lilly has also offered direct-to-patient pricing through LillyDirect for Zepbound, which provides an additional access option not available for semaglutide products.

If your insurance covers either medication for your diagnosis, that coverage is almost always the determining factor in your cost, and semaglutide’s longer coverage history gives it a mild edge in accessibility for diabetic patients.

GoodRx and Discount Pricing

Neither medication looks dramatically different through GoodRx. Ozempic typically runs $800 to $950 through discount programs depending on pharmacy and dose. Mounjaro and Zepbound run similarly, often between $900 and $1,100. Wegovy tends to remain the most expensive option even with discount cards applied.

For detailed breakdowns of discount pricing on each medication, GoodRx Ozempic Price and Tirzepatide Cost on GoodRx cover the specifics. The short version is that GoodRx helps at the margins but doesn’t fundamentally change the affordability picture for either medication.

Compounded Versions: Where the Real Savings Are

For patients without qualifying insurance coverage, compounded semaglutide and compounded tirzepatide are where the cost conversation gets genuinely interesting.

Both medications are available through FDA-registered compounding pharmacies at prices well below their brand-name equivalents. The comparison looks roughly like this:

Compounded semaglutide through a telehealth provider typically runs between $179 and $400 per month depending on dose. Compounded tirzepatide typically runs between $250 and $500 per month depending on dose.

Semaglutide has a modest price advantage in the compounded market. This makes some intuitive sense: semaglutide has been available longer, compounding infrastructure for it is more established, and the raw ingredient costs reflect that maturity.

That said, the gap between compounded semaglutide and compounded tirzepatide is far smaller than the gap between their brand-name counterparts. If tirzepatide is a better clinical fit for you, the incremental cost difference in the compounded market is unlikely to be a decisive factor.

Weighing Cost Against Clinical Outcomes

This is the part of the comparison that matters most for long-term planning. Tirzepatide consistently produces stronger weight loss outcomes in clinical research. The SURMOUNT-1 trial published in the New England Journal of Medicine (Jastreboff et al., 2022) showed average weight loss of 20.9 percent of body weight at the highest tirzepatide dose over 72 weeks. Comparable semaglutide trials showed approximately 15 percent.

That 5 to 6 percentage point difference is meaningful for many patients, and it’s worth factoring into a cost-per-outcome calculation rather than just a cost-per-month comparison. If tirzepatide produces faster or more complete results for a given patient, the higher monthly cost may translate to fewer total months of treatment needed to reach goals.

Consider this scenario: a patient who loses their target weight in 12 months on tirzepatide at $350 per month (compounded) versus 18 months on semaglutide at $250 per month (compounded) ends up spending roughly $4,200 versus $4,500 total, despite tirzepatide’s higher monthly price.

That math doesn’t work out the same way for everyone, and many patients do exceptionally well on semaglutide. But it’s a useful framing for thinking beyond the monthly sticker price.

Manufacturer Savings Programs

Both manufacturers offer savings cards with similar structures and similar limitations. Novo Nordisk’s programs for Ozempic and Wegovy, and Eli Lilly’s programs for Mounjaro and Zepbound, are all designed for commercially insured patients whose plans cover the medication. Neither is accessible to Medicare or Medicaid patients, and neither functions as a standalone discount for fully uninsured individuals.

If you qualify for either savings program, the cost difference between semaglutide and tirzepatide brands largely disappears since both can be brought down to modest copay levels. If you don’t qualify, the compounded market is where the practical comparison lives.

Making the Call

For patients with insurance coverage, the medication your plan covers at the best tier is almost always the right starting point, regardless of which molecule that turns out to be. For patients without coverage, the decision comes down to a combination of clinical fit and budget.

Semaglutide has a slight cost edge in the compounded market and a longer coverage history through insurance. Tirzepatide produces stronger average outcomes and has a direct-to-patient pricing option through LillyDirect for the brand version. Neither answer is universally right.

What is universally true is that the medication you can afford to stay on consistently will produce better outcomes than the one you start and stop because costs become unmanageable. Take the TrimRx intake quiz to find out which option fits your health profile and budget, and a provider will help you work through the decision.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.